Researcher
Erwin Dreesen
- Disciplines:Biomarker evaluation, Biopharmaceutics, Pharmacodynamics, Pharmacokinetics, Pharmacotherapy, Computational biomodelling and machine learning
Affiliations
- Department of Pharmaceutical and Pharmacological Sciences (Department)
Member
From1 Oct 2021 → 30 Sep 2022 - Clinical Pharmacology and Pharmacotherapy (Division)
Member
From1 Oct 2019 → Today - Therapeutic and Diagnostic Antibodies (Division)
Member
From1 Sep 2014 → 30 Sep 2019
Projects
11 - 15 of 15
- A Pharmacometrics Approach to Improve Dose Individualisation Methods of Biologicals in Patients with Chronic Inflammatory DiseasesFrom13 Oct 2020 → TodayFunding: FWO Strategic Basic Research Grant
- Development and streamlining a validation and implementation workflow for model-informed precision dosing for biologicals and antimicrobialsFrom1 Oct 2020 → 30 Sep 2022Funding: IOF - technology validation in lab
- A Pharmacometrics Approach to Guide Dose Optimization of anti-infective drugs in special patient populationsFrom1 Oct 2020 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Pharmacometric models for improved therapeutic drug monitoring of ceftriaxone, posaconazole and infliximabFrom1 Oct 2019 → 30 Sep 2022Funding: FWO fellowships
- Pharmacometric models to improve therapeutic drug monitoring of monoclonal antibodies in the treatment of inflammatory bowel diseasesFrom1 Sep 2014 → 7 May 2019Funding: BOF - Doctoral projects
Publications
1 - 10 of 96
- Therapeutic drug monitoring of monoclonal antibodies in chronic inflammatory diseases: A snapshot of laboratories and applications across Europe(2024)
Authors: Erwin Dreesen
- Agreement Between a Colorimetric Assay and Ultra-Performance Liquid Chromatography-Tandem Mass Spectrometry for Quantifying Paracetamol Plasma Concentrations(2024)
Authors: Erwin Dreesen, Karel Allegaert, Lorenz Van der Linden, Jos Tournoy
- Therapeutic Drug Monitoring 2.0: Time to Assemble the Puzzle(2024)
Authors: Zhigang Wang, Erwin Dreesen
Pages: 316 - 317 - Identifying risk factors of anti-TNF induced skin lesions and other adverse events in paediatric patients with inflammatory bowel disease(2024)
Authors: Karen van Hoeve, Debby Thomas, Ilse Hoffman, Erwin Dreesen
Pages: 95 - 104 - TRPA1 Antagonist LY3526318 Inhibits the Cinnamaldehyde-Evoked Dermal Blood Flow Increase: Translational Proof of Pharmacology(2023)
Authors: Dorien Bamps, Erwin Dreesen, Heleen Marynissen
Pages: 1093 - 1103 - Therapeutic Drug Monitoring Can Guide the Intravenous-to-Subcutaneous Switch of Infliximab and Vedolizumab: A Simulation Study(2023)
Authors: Zhigang Wang, Bram Verstockt, João Guedelha Sabino, Marc Ferrante, Séverine Vermeire, Erwin Dreesen
Pages: 3188 - 3190 - Isavuconazole Exposure in Critically Ill Patients Treated with Extracorporeal Membrane Oxygenation: Two Case Reports and a Narrative Literature Review(2023)
Authors: Beatrijs Mertens, Omar Elkayal, Erwin Dreesen, Joost Wauters, Yves Debaveye, Pieter Vermeersch, Matthias Gijsen
- Drug Repurposing for Targeting Myeloid-Derived Suppressor-Cell-Generated Immunosuppression in Ovarian Cancer: A Literature Review of Potential Candidates(2023)
Authors: Yani Berckmans, Yannick Hoffert, Erwin Dreesen, An Coosemans
- A Model-Based Tool for Guiding Infliximab Induction Dosing to Maximize Long-term Deep Remission in Children with Inflammatory Bowel Diseases(2023)
Authors: Wannee Kantasiripitak, Debby Thomas, Ilse Hoffman, Marc Ferrante, Séverine Vermeire, Karen van Hoeve, Erwin Dreesen
Pages: 896 - 908 - A personalised taper-to-target strategy with adalimumab in Crohn's disease(2023)
Authors: Erwin Dreesen, Bram Verstockt
Pages: 293 - 294